期刊文献+

肺癌血清肿瘤标志物的研究现状 被引量:51

Current status of serum tumor markers in lung cancer
下载PDF
导出
摘要 血清肿瘤标志物的检测,对肺癌的早期诊断、组织学分型、临床分期、预后判断和疗效监测都具有重要应用价值。本文对癌胚抗原、细胞角蛋白19片段、胃泌素释放肽前体、基质金属蛋白酶和肿瘤M2型丙酮酸激酶等肺癌相关血清肿瘤标志物的研究现状作一综述。 The determination of serum tumor markers is of great value for early diagnosis, classification of pathological types and clinical staging in patients with lung cancer. It is also useful in evaluation of prognosis and response to treatment. This article reviews the current status of serum tumor markers in lung cancer, such as CEA, CYFRA21-1, ProGRP, MMPs, TU M2-PK and so on.
出处 《国际内科学杂志》 CAS 2007年第2期73-76,共4页 International Journal of Internal Medicine
关键词 肺癌 肺瘤标志物 Lung cancer Tumor marker
  • 相关文献

参考文献20

  • 1Shitrit D, Zingerman B, Shitrit AB, et al. Diagnostic value of CYFRA 21-1, CEA, CA 19-9,CA 15-3, and CA 125 assays. in pleural effusions: analysis of 116 cases and review of the literature. Oncologist, 2005,10(7) :501-507.
  • 2高云朝,王美琴,陆云,程伟,张学平,刘兴党,林祥通.血清肿瘤标志物的检测对肺癌患者的诊断价值[J].中华结核和呼吸杂志,2005,28(4):268-269. 被引量:32
  • 3杨谨,李蓉,李昂,李恩孝,王晓琴.胃泌素释放肽前体片段31-98检测对小细胞肺癌的临床意义[J].中华肿瘤杂志,2000,22(3):216-218. 被引量:30
  • 4Tamura M, Ohta Y, Nakamura H, et al. Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer. Int J Biol Markers, 2002,17(4) :275-297.
  • 5Kido Y. Vascular endothelial growth factor(VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med J, 2001,48 ( 1 ) :43-47.
  • 6Niklinska W, Burzykowski T, Chyczewski LO, et al. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC) : association with p53 gene mutation and prognosis. Lung Cancer, 2001,34( Suppl 2) : S59-64.
  • 7Park SH, Lee SS. The relationship between serum VEGF concentration and prognosis of lung cancer. Korean J Intern Med, 2003,18(4) :207-211.
  • 8Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives.Oncologist, 2001,6(5) :415-416.
  • 9Ylisimio S, Hoyhtya M, Makitaro R, et al. Elevated serum levels of type Ⅰ collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res, 2001,7(76) :1633-1637.
  • 10Ylisimio S, Hoyhtya M, Turpeenniemi H. Serum matrix metalloproteinases 2,9 and tissue inhibitors of metallproteinases 1,2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res, 2000,20(2B) :1311-1316.

二级参考文献15

  • 1Weinberger SR,Morris TS,Pawlak M.Recent trends in protein biochip technology.Pharmacogenomics,2000,1(4):395-416.
  • 2Gold P,Freedman SO.Specific carcinoembryonic antigens of the human digestive system.J Exp Med,1965,122(3):467-481.
  • 3Okusaka T,Clin Cancer Res,1997年,3期,123页
  • 4Hanley J A,Radiology,1982年,143期,2936页
  • 5Grmec S, Gasparovic V. Comparison of APACHE II,MEES and Glasgow Coma Scale in patients with nontraumatic coma for prediction of mortality.Critical Care, 2001, 5:19-23.
  • 6Schneider J,Philipp M,Velcovsky HG,et al.Pro-gastrin-releasing peptide (ProGRP),neuron specific enolase(NSE),carcinoembryonic antigen(CEA) and cytokeratin 19-fragments(CYFRA21-1)in patients with lung cancer in comparison to other lung diseases.Anticancer Res,2003,23:885-894.
  • 7Barradas PA,Cristovao MM,Costa AM,et al.Comparison of three serum (CYFRA21-1,NSE and CEA)in lung cancer:diagnosis efficacy,prognostic importance,value in chemotherapy monitoring and in early prediction of relapse.Chest,1998,114:250s-255s.
  • 8Nakayama M,Satoh H,Ishikawa H,et al.Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest,2003,123:2001-2006.
  • 9Miedouge M,Rouzaud P,Salama G,et al.Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.Br J Cancer,1999,81:1059-1065.
  • 10Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med, 2004, 350:379-392.

共引文献73

同被引文献351

引证文献51

二级引证文献428

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部